Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089189 | PMC |
| http://dx.doi.org/10.1073/pnas.2217389120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
J Natl Cancer Inst
December 2024
Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Background: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER <1%) and ER-intermediate (ER 10%-50%) tumors.
Methods: Among 921 patients with early-stage I-III, ER ≤50%, HER2-negative BCs, tumors were classified as ER-negative (n = 712), ER-low (n = 128), or ER-intermediate (n = 81).
Reply to Miglietta: Toward doing rigorous and innovative science with nonmodel organisms.
Proc Natl Acad Sci U S A
March 2023
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Ciberonc, Universidad de Oviedo, Oviedo 33006, Spain.